CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer
DOI 10.1055/s-0030-1263569
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Moehler, J Hartmann, F Lordick, S Al-Batran, P Reimer, S Daum, T Trarbach, M Ebert, C Schimanski, P Galle
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe08/2010
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Since sunitinib is effective in metastatic renal cancer and GIST tumors, we evaluated tolerability and efficacy of sunitinib for the first time in highly pretreated caucasian patients (pts) with unresectable metastatic (met.) adenocarcinoma of stomach, esophagogastric junction or lower oesophagus. Methods: 52 caucasian pts were included after documented resistance to 5-FU, cisplatin, oxaliplatin, irinotecan an…
Zitieren
Zitierempfehlung
M Moehler, J Hartmann, F Lordick, S Al-Batran, P Reimer, S Daum, T Trarbach, M Ebert, C Schimanski, P Galle (2010) An open-label, multicenter phase II trial of SUNITINIB for patients with chemorefractory metastatic gastric cancer. Zeitschrift für Gastroenterologie (08). https://doi.org/10.1055/s-0030-1263569
Mit CareLit weiterarbeiten